drugset / Trial / NCT03824080
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
Phase 2
Completed
45 enrolled
GWT-TUD GmbH
Amsterdam UMC, location VUmc · collabBerGenBio ASA · collabGroupe Francophone des Myelodysplasies · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm multicenter, phase II study. The primary objective is to assess the efficacy of bemcentinib (BGB324) a highly selective inhibitor of the AXL receptor tyrosine kinase for the treatment of AML and MDS patients failing or being refractory to first line hypomethylating agent (HMA) treatment. Furthermore, safety, disease progression, treatment failure will be assessed. A total of 43 patients will be included in the trial.
Timeline
- Start
- 2018-12-20
- Primary completion
- 2020-07-13
- Completion
- 2021-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemcentinib | Small molecule | 200 mg | Oral |